Skip to Content

Ignacio I. Wistuba, M.D.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
2130 W Holcombe Blvd
Life Science Plaza Building
Unit Number: 2951
Houston, TX 77030
Room Number: LSP9.4029
Phone: (713) 563-9184
Fax: (713) 834-6082
Email: iiwistuba@mdanderson.org

Education & Training

Degree-Granting Education

1985 Austral University of Chile, Valdivia, Chile, MD, Medicine
1983 Austral University of Chile, Valdivia, Chile, Undergraduate, Medical School Undergraduate

Postgraduate Training

9/1995-3/1999 Postdoctoral, Molecular Pathology, Hamon Center for Therapeutic Oncology Research Center, UT Southwestern Medical Center, Dallas, TX
3/1994-2/1995 Postdoctoral, Pathology Research, UT Southwestern Medical Center & Simmons Cancer Center, Department of Pathology, Dallas, TX
3/1986-2/1989 Pathologist, Pathology, Catholic University of Chile, Santiago, Chile

Board Certifications

4/1989 Anatomic Pathology, Chile

Experience/Service

Academic Appointments

Professor, Department of Pathology - Research, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-8/2012
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (joint appointment), Houston, TX, 7/2003-9/2008
Associate Professor, Department of Pathology - Research, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2003-8/2008
Associate Professor, Department of Pathology, Catholic University of Chile, Santiago, Chile, 8/2002-7/2003
Instructor, Hamon Center for Therapeutic Oncology Research Center, UT Southwestern Medical Center, Dallas, TX, 3/1998-2/1999
Assistant Professor, Department of Pathology, Catholic University of Chile, Santiago, Chile, 9/1995-2/2002
Assistant Professor, Honorary Appointment, Department of Pathology, University of La Frontera, Temuco, Chile, 3/1989-6/1995

Administrative Appointments/Responsibilities

Director of the UT-Lung SPORE Tissue Bank, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2003-present

Other Appointments/Responsibilities

Lung Cancer Pathologist of the Lung Cancer Committee, Southwestern Oncology Group (SWOG), Ann Arbor, MI, 2/2009-present
Chair of the MD Anderson Cancer Center Steering Committee Clinical Alemana (Santiago, Chile) Sister Institution Agreement, The University of Texas MD Anderson Cancer Center, Santiago, Chile, 2/2006-4/2007

Institutional Committee Activities

Member, The University of Texas Graduate School of Biomedical Sciences, 1/2013-present
Member, MD Anderson Cancer Center Southwestern Oncology Group (SWOG) Executive Committee, 2/2009-present
Member, MD Anderson Cancer Center Thoracic/Head and Neck Medical Oncology Trial Committee, 4/2004-6/2007

Selected Publications

Peer-Reviewed Original Research Articles

1. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118(11):2889-99, 6/2012. e-Pub 10/2011. PMCID: PMC3369269.
2. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118(9):2454-65, 5/2012. e-Pub 9/2011. PMCID: PMC3298843.
3. Kadara H, Kabbout M, Wistuba II. Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17(1):50-65, 1/2012. e-Pub 10/2011. PMID: 22040022.
4. Sen B, Peng S, Woods DM, Wistuba II, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18(1):127-39, 1/2012. e-Pub 11/2011. PMCID: PMC3251692.
5. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. J Thorac Oncol 6(12):2104-11, 12/2011. PMID: 21892101.
6. Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical Overexpression of Platelet-Derived Growth Factor Receptor-Beta (PDGFR-ß) is Associated With PDGFRB Gene Copy Number Gain in Sarcomatoid Non-Small-Cell Lung Cancer. Clin Lung Cancer 12(6):369-74, 11/2011. e-Pub 5/2011. PMID: 21729646.
7. Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression. Mol Cell Biol 31(21):4270-85, 11/2011. e-Pub 9/2011. PMCID: PMC3209326.
8. Zhang YA, Maitra A, Hsieh JT, Rudin CM, Peacock CD, Karikari C, Brekken RA, Stastny V, Gao B, Girard L, Wistuba I, Frenkel E, Minna JD, Gazdar AF. Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther 12(7):617-28, 10/2011. e-Pub 10/2011. PMCID: PMC3218386.
9. Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 17(17):5705-14, 9/2011. e-Pub 7/2011. PMCID: PMC3166982.
10. Kim ES, Herbst RS, Wistuba I, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1(1):44-53, 6/2011. e-Pub 6/2011. PMID: 22586319.
11. Zochbauer-Muller S, Wistuba II, Minna JD, Gazdar AF. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer 2(2):141-5, 11/2000. PMID: 14731325.
12. Wistuba II, Tomlinson GE, Behrens C, Virmani A, Geradts J, Blum JL, Minna JD, Gazdar AF. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Genes Chromosomes Cancer 28(4):359-69, 8/2000. PMID: 10862044.
13. Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 6(7):2604-10, 7/2000. PMID: 10914700.
14. Larramendy ML, Lushnikova T, Bjorkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, Gazdar AF, Knuutila S. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet 119(2):132-8, 6/2000. PMID: 10867149.
15. Lerman MI, Minna JD. for the International Lung Cancer Chromosome 3p21.3 tumor suppressor gene consortium. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 60:6116-6133, 2000.

Grant & Contract Support

Title: LUNGevity Foundation Grant
Funding Source: LUNGevity
Role: Co-Investigator
Principal Investigator: D. Carbone, Vanderbilt University
Duration: 8/15/2013 - 8/14/2015
 
Title: Discovery of New Drugs for the Treatment of Lung Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Duration: 6/1/2011 - 5/31/2016
 
Title: Profile Molecular Markers in NSCLC Tissue Microarrays and Full Slide Sections
Funding Source: Pfizer
Role: Co-Investigator
Duration: 6/1/2011 - 5/31/2014
 
Title: A Biomarker-integrated Study in Previously Treated Patients with Non-Small Cell Lung Cancer (BATTLE-II).
Funding Source: Merck and Company
Role: Co-Investigator
Principal Investigator: V Papadimitrakopoulou
Duration: 12/10/2010 - 12/31/2014
 
Title: Personalizing Medicine: The Identification of Biomarkers for Predicting Response to Treatment in Advanced Non-Small Cell Lung Cancer
Funding Source: V Foundation
Role: Principal Investigator
Duration: 10/1/2010 - 3/31/2014
 
Title: Predicting Adjuvant Chemotherapy Response in Lung Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Xie
Duration: 9/1/2010 - 2/28/2015
 
Title: Transdisciplinary Research in Lung Cancer (TRICL)
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 7/9/2010 - 6/30/2014
 
Title: Molecular profiles for lung cancer pathogenesis and detection in US Veterans
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 7/1/2010 - 6/30/2014
 
Title: Role of CREB in Lung Cancer Development
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: J. Koo
Duration: 4/1/2010 - 3/31/2015

Last updated: 7/2/2014